Here's a tough day in biotech: uniQure N.V. (QURE) announced that the U.S. Food and Drug Administration has delivered some bad news about its lead candidate. The agency has advised the company that data from its Phase 1/2 study of AMT-130, an investigational gene therapy for Huntington's disease, shouldn't be used as the primary evidence to support a marketing application.
Instead, the FDA strongly recommended that uniQure run a new study—a prospective, randomized, double-blind trial with a sham surgery control group—if it wants to move forward. This is essentially the FDA saying the current data package isn't convincing enough on its own to prove the therapy works. They want a more rigorous, head-to-head comparison against a placebo before considering approval.
This is a significant pivot from where uniQure thought it stood. Back in November 2025, the company believed it was on track, having shared its study protocols and analysis plans with the FDA in advance. The new feedback indicates the agency currently disagrees that comparing the AMT-130 data to an external control group is adequate for a Biologics License Application (BLA) submission.
So, what's next? uniQure isn't giving up. The company plans to request a formal Type B meeting with the FDA in the second quarter of 2026 to hash things out.
"While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA's stated commitment to regulatory flexibility may be appropriately applied in this setting," said Matt Kapusta, CEO at uniQure. "We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130."
In other words: We think our data is strong and lasting, and we hope to convince the FDA to see it our way. Let's talk.
This setback for AMT-130 comes as uniQure is working on a whole pipeline of other gene therapies. The company is targeting severe diseases like refractory temporal lobe epilepsy, ALS, and Fabry disease.
Just last month, uniQure shared some early, preliminary data from 11 patients in its Phase 1/2a trial for AMT-191, a gene therapy for Fabry disease. The results showed dose-dependent increases in an enzyme called α-Gal A activity. The boosts ranged widely—from less than half a fold to over 300 times the normal level—depending on the dose given. It's early data, but it shows the therapy is doing something biologically.
The company has also completed enrolling the first group of patients in a Phase 1/2a study for AMT-260, targeting a form of epilepsy, with more clinical data expected in the first half of 2026.
It's worth noting that uniQure isn't new to this game. The company has a previous success with a gene therapy for hemophilia B, which shows it has the technical chops for genomic medicine. Financially, the company reported having about $622.5 million in cash, cash equivalents, and current investment securities as of the end of 2025. It expects that war chest to fund its operations into the second half of 2029, which gives it some runway to navigate this regulatory delay.
But for now, investors are focused on the immediate shock. uniQure shares were down a staggering 43.38% at $8.85 in premarket trading on Monday. That puts the stock perilously close to its 52-week low of $7.76.
The story here is a classic biotech narrative: high hopes for an accelerated path to market for a serious disease, followed by a regulatory reality check that demands more time, more patients, and more money. All eyes are now on that planned meeting in 2026 to see if a compromise can be found.
